P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease
Status:
RECRUITING
Trial end date:
2026-08-11
Target enrollment:
Participant gender:
Summary
This is an open label, two to three center study to evaluate the clinical efficacy and safety of 1 dose level of 2-hydroxypropyl-β-cyclodextrin (2-HPβCD) given intravenously in adult patients with type 2 diabetes with diabetic kidney disease (DKD) and proteinuria.